SK Biopharmaceuticals Co (XKRX:326030) Total Liabilities : ₩451,425 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co Total Liabilities?

SK Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 was ₩451,425 Mil.

SK Biopharmaceuticals Co's quarterly Total Liabilities declined from Sep. 2023 (₩428,561.70 Mil) to Dec. 2023 (₩402,219.38 Mil) but then increased from Dec. 2023 (₩402,219.38 Mil) to Mar. 2024 (₩451,424.68 Mil).

SK Biopharmaceuticals Co's annual Total Liabilities increased from Dec. 2021 (₩199,464.89 Mil) to Dec. 2022 (₩347,680.68 Mil) and increased from Dec. 2022 (₩347,680.68 Mil) to Dec. 2023 (₩402,219.38 Mil).

SK Biopharmaceuticals Co Total Liabilities Historical Data

The historical data trend for SK Biopharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Biopharmaceuticals Co Total Liabilities Chart

SK Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

152,098.40

121,174.85

199,464.89

347,680.68

402,219.38

SK Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															339,779.60	339,428.99	428,561.70	402,219.38	451,424.68

SK Biopharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SK Biopharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	241618.589	+	(120989.231	+	39611.563
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	402,219

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	723170.577	-	320951.195
	=	402,219

SK Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	355417.738	+	(52242.371	+	43764.574
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	451,425

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	791491.643	-	340066.961
	=	451,425

SK Biopharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of SK Biopharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Biopharmaceuticals Co (XKRX:326030) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbp.com

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

SK Biopharmaceuticals Co (XKRX:326030) Headlines

No Headlines